Insulet (Nasdaq: PODD ) reported earnings on May 9. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Insulet met expectations on revenues and missed expectations on earnings per share.
Compared with the prior-year quarter, revenue increased significantly and GAAP loss per share improved.
Gross margins shrank, operating margins expanded, net margins improved.
Insulet recorded revenue of $47.8 million. The 18 analysts polled by S&P Capital IQ looked for revenue of $47.5 million on the same basis. GAAP reported sales were 69% higher than the prior-year quarter's $28.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.31. The 14 earnings estimates compiled by S&P Capital IQ forecast -$0.28 per share. GAAP EPS were -$0.31 for Q1 compared to -$0.22 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 42.5%, 540 basis points worse than the prior-year quarter. Operating margin was -22.8%, 290 basis points better than the prior-year quarter. Net margin was -31.0%, 390 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $51.6 million. On the bottom line, the average EPS estimate is -$0.25.
Next year's average estimate for revenue is $215.2 million. The average EPS estimate is -$0.89.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 67 members out of 108 rating the stock outperform, and 41 members rating it underperform. Among 40 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 27 give Insulet a green thumbs-up, and 13 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Insulet is outperform, with an average price target of $23.65.
The health-care investing landscape is littered with also-rans and a few major winners. Is Insulet performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Get instant access to this free report.
- Add Insulet to My Watchlist.